Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P17931 (
galectin-3
)
2,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Galectin-3
is a member of the galectin family and belongs to a group of soluble beta-galactoside-binding animal lectins. The molecule is expressed by neural and nonneural cells intra- (cytoplasm and nucleus) as well as extra-cellularly (plasma membrane and extracellular space). By using an in vitro cell-substratum adhesion assay, we have addressed the question whether
galectin-3
present in the extracellular milieu may support the adhesion and/or neurite outgrowth of neural cells in a manner analogous to cell adhesion molecules.
Galectin-3
was immobilized as a substratum and various cell types, N2A (neuroblastoma), PC12 (
pheochromocytoma
), and TSC (transformed Schwann cells) cell lines, neural cells from early postnatal mouse cerebellum, and dorsal root ganglion neurons from newborn mice were allowed to adhere to the lectin. Here we show that all cell types studied specifically adhered to
galectin-3
by the following criteria: 1) the number of adherent cells was dependent on the
galectin-3
concentration used for coating; 2) adhesion of cells to
galectin-3
, but not to collagen type I or laminin was inhibited by polyclonal antibodies to
galectin-3
; 3) upon addition of asialofetuin (a polyvalent carrier of terminal beta-galactosides) to the cell suspension prior to the adhesion assay, cell adhesion to
galectin-3
was inhibited in a dose-dependent manner; and 4) cell adhesion to
galectin-3
was abolished by treatment of cells with endo-beta-galactosidase. In addition, the adhesion of dorsal root ganglion neurons to
galectin-3
could be inhibited by lactose. Notably, substratum-bound
galectin-3
promoted the outgrowth of neurites from dorsal root ganglia explants and this neurite outgrowth promoting activity could be inhibited by polyclonal antibodies to
galectin-3
.
...
PMID:Galectin-3 promotes neural cell adhesion and neurite growth. 984 55
Unless distant metastases or local invasion are present, the diagnosis of malignant
pheochromocytoma
is challenging. Hence, biological markers are sought after and we thought to examine
galectin-3
in such a role. Four malignant and 24 benign (10 sporadic, 14 hereditary) pheochromocytomas were analyzed for the expression of
galectin-3
. One malignant
pheochromocytoma
with distant metastases showed strong and one malignant undifferentiated
pheochromocytoma
with local invasion showed partly strong cytoplasmic staining. Nine of 10 sporadic and all hereditary benign pheochromocytomas had absent/weak staining. One benign sporadic
pheochromocytoma
had moderate cytoplasmic staining. The distinct expression in various types of pheochromocytomas is intriguing and requires further investigation.
...
PMID:Distinct expression of galectin-3 in pheochromocytomas. 1710 25
Currently, the only reliable indicator of malignancy in
pheochromocytoma
is the presence of distant metastasis or extensive local invasion; predicting behavior of
pheochromocytoma
remains challenging. We aimed to correlate the behavior of
pheochromocytoma
with its expression of nm-23, cyclooxygenase (COX)-2, and
galectin-3
(genes used to predict the course of some neoplastic diseases), evaluated immunohistochemically in 55 paraffin blocks of formalin-fixed
pheochromocytoma
specimens with confirmed behavior. In 3 (7%) of 44 benign and 7 (64%) of 11 malignant pheochromocytomas, there was negative nm-23 expression (P = .000). COX-2 immunoreactivity was positive in 10 (23%) of benign and 9 (82%) of malignant tumors (P = .000).
Galectin-3
was expressed in 5 (11%) of benign and 9 (82%) of malignant pheochromocytomas (P = .000). Negative nm-23, along with positive COX-2 or
galectin-3
, predicted malignancy with 100% specificity. Dual negativity for
galectin-3
and COX-2, along with nm-23 positivity, indicated benign behavior with 100% sensitivity. In early
pheochromocytoma
, evaluation of nm-23,
galectin-3
, and COX-2 expression could predict the outcome. Larger studies seem necessary to confirm the potential practical value of our findings.
...
PMID:Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma. 2135 Jan 2